Mcmaster University
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1887-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.mcmaster.ca
Clinical Trials
714
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (604 trials with phase data)• Click on a phase to view related trials
Evaluating a Digital Cognitive Training Intervention in Adults With ADHD
- Conditions
- ADHD
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 52
- Registration Number
- NCT07050225
Physiotherapist Navigator Pilot Trial
- Conditions
- Cancer
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 26
- Registration Number
- NCT07045740
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
Piloting and Evaluation of a Group Intervention for People With Psychosis Designed to Boost Access and Usage of ICT
- Conditions
- Serious Mental Illness
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 18
- Registration Number
- NCT07025499
- Locations
- 🇨🇦
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
Reducing Pain in Complex Regional Pain Syndrome Using Personalized Brain Stimulation: A Feasibility Study
- Conditions
- Complex Regional Pain Syndrome (CRPS)
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 10
- Registration Number
- NCT06987747
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
Therapeutic Relevance of Abnormal Airway Morphology in Asthma
- Conditions
- Asthma
- Interventions
- Drug: Inhaled corticosteroid (ICS)Drug: Oral Corticosteroid (OCS)
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 242
- Registration Number
- NCT06970080
- Locations
- 🇨🇦
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
🇨🇦Western University, London, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 138
- Next
News
Fifty1 AI Labs Completes Landmark Phase III REVIVE Trial for Long COVID Treatment
Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.
McMaster's Inhaled COVID-19 Vaccine Shows Promise in Phase 1 Trials, Advances to Phase 2
McMaster University's inhaled COVID-19 vaccine demonstrated safety and immunogenicity in a Phase 1 trial of 36 healthy adults, with results published in Nature Communications.
ERA 2025 to Feature Pivotal Nephrology Trials Including CONFIDENCE, ACHIEVE, and VISIONARY Studies
The 62nd European Renal Association Congress in Vienna will present seven late-breaking clinical trials addressing chronic kidney disease, dialysis patients, and glomerular disease developments.
CLEAR OASIS 9 Trial: Colchicine and Spironolactone Show Limited Benefits After Myocardial Infarction
Late-breaking results from the CLEAR OASIS 9 trial reveal that colchicine failed to reduce cardiovascular events after myocardial infarction despite lowering inflammatory markers.
New Antibiotic Class Discovered in Soil Sample Could Combat Drug-Resistant Bacteria
Researchers have identified lariocidin, the first new class of antibiotics to reach the market in nearly 30 years, discovered in bacteria from backyard soil samples.
McMaster University Launches Phase-2 Trial of Novel Inhaled COVID-19 Vaccine
Canadian researchers at McMaster University have begun phase-2 clinical trials for AeroVax, an innovative inhaled COVID-19 vaccine that directly targets the lungs and upper airways where infection begins.
Global Study Reveals Critical Underutilization of Secondary Prevention Medications for Cardiovascular Disease
A comprehensive 12-year PURE study across 17 countries shows significant underutilization of secondary prevention medications for cardiovascular disease, with usage rates dropping to 31.3% in the final study visit.